Ponatinib versus imatinib for newly diagnosed chronic myeloid leukaemia: an international, randomised, open-label, phase 3 trial
Lipton, Jeffrey H, Prof, Chuah, Charles, MD, Guerci-Bresler, Agnès, MD, Rosti, Gianantonio, Prof, Simpson, David, Prof, Assouline, Sarit, MD, Etienne, Gabriel, MD, Nicolini, Franck E, MD, le Coutre, Philipp, Prof, Clark, Richard E, Prof, Stenke, Leif, MD, Andorsky, David, MD, Oehler, Vivian, MD, Lustgarten, Stephanie, PhD, Rivera, Victor M, PhD, Clackson, Timothy, PhD, Haluska, Frank G, MD, Baccarani, Michele, Prof, Cortes, Jorge E, Prof, Guilhot, François, Prof, Hochhaus, Andreas, Prof, Hughes, Timothy, Prof, Kantarjian, Hagop M, Prof, Shah, Neil P, Prof, Talpaz, Moshe, Prof, Deininger, Michael W, Prof
Published in The lancet oncology (01.05.2016)
Published in The lancet oncology (01.05.2016)
Get full text
Journal Article
Nilotinib versus imatinib for the treatment of patients with newly diagnosed chronic phase, Philadelphia chromosome-positive, chronic myeloid leukaemia: 24-month minimum follow-up of the phase 3 randomised ENESTnd trial
Kantarjian, Hagop M, Prof, Hochhaus, Andreas, Prof, Saglio, Giuseppe, Prof, De Souza, Carmino, Prof, Flinn, Ian W, MD, Stenke, Leif, MD, Goh, Yeow-Tee, MD, Rosti, Gianantonio, Prof, Nakamae, Hirohisa, MD, Gallagher, Neil J, MD, Hoenekopp, Albert, MD, Blakesley, Rick E, PhD, Larson, Richard A, Prof, Hughes, Timothy P, Prof
Published in The lancet oncology (01.09.2011)
Published in The lancet oncology (01.09.2011)
Get full text
Journal Article